East Ocean Development

Innovent Biologics is a leading biopharmaceutical company based in China, dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for oncology, metabolic, autoimmune, and ophthalmic diseases. Founded in 2011 by Dr. Michael Yu, the company utilizes East Ocean Development Limited as a primary holding and intellectual property vehicle. Innovent's flagship product is Tyvyt (sintilimab), a PD-1 inhibitor co-developed with Eli Lilly that has achieved significant commercial success and National Reimbursement Drug List (NRDL) inclusion in China. The company boasts a robust pipeline of over 30 assets, including monoclonal antibodies, bispecifics, and antibody-drug conjugates. Innovent has established strategic global partnerships with major pharmaceutical firms such as Roche, Sanofi, and Incyte to expand its international footprint and therapeutic reach.